Pharnext partners with Galapagos
Neurodegeneration specialist Pharnext SA and autoimmune disease expert Galapagos NV have inked an R&D contract in order to expand Pharnext’s pleotherapy approach to new indications.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
Entries by Thomas Gabrielczyk
BerGenBio plans IPO and partners with MSD
Norwegian BerGenBio ASA said it will go public at Oslo Børs and partnered with Merck & Co. for conducting Phase II combination studies of its oral Axl kinase blocker BGB324 with Merck’s PD-1 inhibitor pembrolizumab in lung cancer patients.
Next Big Thing in insurance: Digitalising Health
To date, insurance business models have always been based on damage control, but that paradigm is changing. Some insurers are now trying to hedge bets by motivating customers to get healthier and track that progress with the help of technology. Critics are concerned about data protection issues, and see this as a first step towards individualised premiums that will erode the principle of solidarity. What are the potential upsides and downsides for customers and societies?
Breath Therapeutics cashes in €43,5m
Inhaled lung therapeutics specialist Breath Therapeutics Holding BV closed a Series A financing led by Gimv and Sofinnova.
PwC reports high productivity of UK Life Sciences
The UK’s Life Sciences sector is more than twice as productive as the UK average, says a new analyst report. However, it doesn’t come close to the productivity in Switzerland or other leading life sciences clusters.
Roche restarts pivotal Gantenerumab tests
MorphoSys AG has announced that its partner Roche plans to start two further pivotal Phase III studies with its licensed Alzheimer’s antibody Gantenerumab.
Sanofi and AZ ink €600m deal for RSV jab
Sanofi’s vaccine arm Sanofi Pasteur has inked a deal with AstraZeneca’s biologics subsidiary MedImmune totaling €615m to acquire co-development rights for MEDI8897, a jab to prevent respiratory syncytial virus (RSV) infection, the most common cause of lung inflammation in infants.
Nestle researchers link IBS to anxiety
Researchers at Nestlé Research Center in Lausanne and Canadian collaborators have found that the microbiome of irritable bowel syndrome patients affects their susceptibility for anxiety disorders.
FDA grants Priority Review to avelumab
Avelumab, Merck KGaA’s and Pfizer’s Phase III checkpoint inhibitor, has been granted Priority Review from the US Food and Drug Administration in urothelial carcinoma patients who progressed on or after platinum-based chemotherapy.
Big Pharma pushing up orphan drug prices
The times in which biotechs dominate the orphan drug market are over. A report from business intelligence provider Evaluate Ltd. concludes that only three in ten OD developers are still biotech SMEs.